AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01145365 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exam under anesthesia (EUA)
Description: EUA established drainage of perianal fistulas \&/or abscesses will be done before patient begins medical therapy with certolizumab (Cimzia)
Study NCT02076204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visiting
Description: MIHOPE-Strong Start will examine local programs that use either of two home visiting service models that have shown previous evidence of improving birth outcomes: Healthy Families America (HFA) and Nurse-Family Partnership (NFP). HFA and NFP provide disadvantaged expectant mothers with individualized in-home services, including assessment of prenatal and postnatal risks to child well-being; referrals to needed health care or social services; and direct education of parents by home visitors on such topics as healthy prenatal behaviors, parenting, and child development.
Study NCT02548377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Study NCT02548377 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Study NCT03103191 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: KL-6 levels
Description: Measure of KL-6 in serum
Study NCT00485069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ROP
Description: Ropinirole Hydrochloride monotherapy group (ROP): Patients will receive ROP tablets 3 times daily. In the 4-week Fixed Titration Phase (from Week 0 as Baseline), the dose will start at 0.75 mg/day and will be increased weekly by 0.75 mg/day up to 3.0 mg/day. In the 48-week Flexible Titration and Maintenance Phase, the dose will be increased by 1.5 mg/day at intervals of at least 1 week up to a maximum of 15.0 mg/day. The dose will be maintained at a level without further symptomatic improvement is expected. Concomitant use of L-dopa is prohibited during the study.
Study NCT00485069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ROP+L-Dopa
Description: Ropinirole Hydrochloride with L-Dopa adjunct therapy group (ROP+L-Dopa): Patients will receive ropinirole hydrochloride (ROP) tablets 3 times daily. In the 4-week Fixed Titration Phase (from Week 0 as Baseline), the dose will start at 0.75 milligrams (mg)/day and will be increased weekly by 0.75 mg/day up to 3.0 mg/day. In the 48-week Flexible Titration and Maintenance Phase, the dose will be increased by 1.5 mg/day at intervals of at least 1 week up to a maximum of 15.0 mg/day. The dose will be maintained at a level without further symptomatic improvement is expected. The dosing regimen of L-dopa remain unchanged from 4 weeks prior to the start of the Screening Phase throughout the study.
Study NCT01116947 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meals during hemodialysis accompanied by lanthanum carbonate to control phosphorus
Description: Based on the hypothesis that the efficacy and potency of Fosrenol enables increasing dietary protein intake and provision of meals during dialysis treatment for improving nutritional status in malnourished dialysis patients with a low serum albumin (\<4.0 g/dL) while serum phosphorus can be effectively controlled with the target range of 3.5 to 5.5 mg/dL
Study NCT03734393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIVD+/R+
Description: Liver from an HIV-infected deceased donor
Study NCT03043742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone Marrow Derived Autologous CD133+ Selected Cell Product
Description: Injection of bone marrow derived autologous CD133+ cell product into laser channels during Trans-Myocardial Revascularization
Study NCT03984396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Materials - Patient & Clinician
Description: deprescribing information for patient \& clinician
Study NCT04101383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RinGlar®
Description: Single subcutaneous administration of RinGlar® in dose 0.6 Units/kg
Study NCT04297631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vancomyscin
Description: Everyone gets the vancomyscin powder.
Study NCT04074668 — intervention group
Intervention type: DRUG
Intervention: Aminohippurate Sodium Inj 20%
Description: Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
Study NCT04101383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus®
Description: Single subcutaneous administration of Lantus® in dose 0.6 Units/kg
Study NCT03851770 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Characterization of Vagus nerve stimulation
Description: Characterization of Vagus nerve stimulation induced larynx evoked motor potential. Patients participating in the study will be asked to come to perform the experiment (duration maximum 1 hour) at the Neurophysiology Department of Saint Luc .
Study NCT03395626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ID-JPL934
Description: probiotics
Study NCT03395626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: corn starch
Study NCT03337815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of MTX and TwHF placebo
Description: Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）placebo：20mg,3 times a day, oral, for 24 weeks.
Study NCT03337815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of TwHF and MTX placebo
Description: Tripterygium wilfordii Hook F（TwHF)：20mg,3 times a day, oral, for 24 weeks.Methotrexate (MTX)placebo: 10-15mg per week according to patient's weight, oral, for 24 weeks.
Study NCT00811694 — intervention group
Intervention type: OTHER
Intervention: ocular blood flow measurements
Description: non-invasive haemodynamic measurements of retinal vessel diameters, laser Doppler flowmetry and laser Doppler velocimetry
Study NCT03909048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive - Psychoeducation
Description: Individuals will receive interactive psychoeducation in the lab over the course of a week period. Each session will take approximately 30 minutes.
Study NCT03909048 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-interactive Psychoeducation
Description: Individuals will receive non-interactive psychoeducation over the course of a week period. Each session will take approximately 30 minutes.
Study NCT00607776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400
Description: Drops
Study NCT00607776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane
Description: Drops
Study NCT03328234 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIB-IMRT
Description: Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.
Study NCT03328234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 45-50mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
Study NCT03328234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-Based Drug
Description: Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
Study NCT03328234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 135-150mg/m2 on day1,every 3 weeks, 2 cycles, 1 month after completion of radiotherapy
Study NCT03328234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-Based Drug
Description: Nedaplatin or Lobaplatin or Cisplatin, 50-80mg/m2 on day1 (Lobaplatin,50mg on day1 ),every 3 weeks, 2 cycles, 1 month after completion of radiotherapy
Study NCT03328234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Involved Field Irradiation (IFI)
Description: CTV was defined as GTV with a 3.0-5.0 cm craniocaudal margin and a 0.6-0.8 cm lateral margin and GTVnd with a 0.5-1.0 cm margin.
Study NCT04534517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJV Investigational Multifocal Contact Lens
Description: TEST Lens
Study NCT04534517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS® with HYDRACLEAR® PLUS
Description: The spherical test lens was used in the troubleshooting steps only for low ADD subjects who have reported a distance vision complaint.
Study NCT02597777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acetyl Hexapeptide-8
Description: Acetyl-Hexapeptide-8 peptide solution will be diluted to a final concentration of 10% using Cetaphil facial lotion base
Study NCT02597777 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vehicle
Description: Water will be diluted to a final concentration of 10% using Cetaphil facial lotion base.
Study NCT03100409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary modification
Description: Dietary intervention will consist on a low residue diet: 20% kcal from fat, 5g lactose/day, 20g fiber/day (5g from insoluble fiber).~Dietary intervention will be adapted to the patient's individual requirements, according to the presence of comorbidities or renal deterioration.~1. No comorbidities. Energy: 20-30 kcal/kg of body weight/day. Protein: 1.3 g/kg of body weight/day.~2. Comorbidities (diabetes, hypertension), or geriatric patient. Energy: 25-30 kcal/kg of body weight/day. Protein: 1.5 g/kg of body weight/day.~3. Renal deterioration. Energy: 30-35 kcal/kg of body weight/day. Protein: 1 g/kg of body weight/day. Sodium: 2000-2300 mg/day. Potassium: 1900-2730 mg/day. Phosphorus: 800-1000 mg/day.
Study NCT01128296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Oral dosing daily starting at 48 hours before first dose of gemcitabine (starting on Day -2) and for a total of 31 days (ending on Day 29), prior to surgical resection. Capsules are available in 200 mg strengths. Daily doses are 200, 400, 600, 800, 1000, or 1200 mg, and will be administered BID for doses above 200 mg.
Study NCT01128296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous administration on Days 1 and 15, with the infusion given at the fixed dose rate of 10mg/m2/min (e.g. 150 min for a 1500 mg/m2 dose).
Study NCT02527629 — intervention group
Intervention type: OTHER
Intervention: Decellularized human heart valves
Description: Decellularized human aortic heart valves
Study NCT03732027 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Transversus Abdominis Plane Block
Description: At the end of operation and after hemostasis, 20 ml of 0.25% bupivacaine will be injected intra-abdominally into the Transversus Abdominis plane at the midpoint of the line connecting the crista iliaca and inferior costal margin and at two locations in the lateral abdominal wall at 3-4 cm inferior to the previous midline injection. The same procedure will be repeated on the opposite side using an identical amount of local anesthetic.
Study NCT03732027 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Rectus Sheath Block
Description: At the end of operation and after hemostasis,20 ml 0.25% bupivacaine will be administered slowly under direct vision after careful aspiration to the rectus sheath space which is present inbetween rectus abdominis muscle and the posterior layer of its sheath at the upper pole of the midline incision by time of closure of the anterior abdominal wall. The procedure will be repeated on the opposite side.
Study NCT02379013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Volunteer with MRI
Description: functional MRI
Study NCT03308422 — intervention group
Intervention type: BEHAVIORAL
Intervention: parental representations
Description: parental representations of the impact of the use of screens on their preschool children health and development
Study NCT04232930 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Four types of music will be provided, including pop, classical, jazz or spa music which are prepared by the study team. They contain instrumental songs only without vocal.
Study NCT03934216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified Dose on Specified Days
Study NCT03934216 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified Dose on Specified Days
Study NCT01824888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JUC solution
Description: 1.5 ml JUC solution rubbing on hands for 30 seconds, repeated twice
Study NCT01824888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propan-2-ol
Description: 1.5 ml propan-2-ol rubbing on hands for 30 seconds, repeated twice
Study NCT01573000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Iodine-131 Anti-B1 Antibody Versus Anti-B1 Antibody in Chemotherapy-Relapsed/Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL)
Description: Subjects will be randomized to receive tositumomab and iodine-131 tositumomab (Arm A) or unlabeled tositumomab (Arm B). Subjects randomized to receive unlabeled tositumomab may crossover and receive radiolabeled Iodine-131 tositumomab following progression of their lymphoma. Response in both arms will be assessed at 7 weeks, 13 weeks, and then at 3-monthly intervals for up to 2 years.
Study NCT00163566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydrotestosterone (0.7%) in hydroalcoholic gel
Description: transdermal gel, 0.7% DHT, 0.35 mg/day or 0.70 mg/day total daily dose (or placebo gel), applied twice per day
Study NCT00163566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dihydrotestosterone (0.7%) in hydroalcoholic gel
Description: transdermal gel, 0.7% DHT, 0.35 mg/day or 0.70 mg/day total daily dose (or placebo gel), applied twice per day
Study NCT04363060 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Azithromycin with amoxicillin/clavulanate
Description: Patients will receive azithromycin 500 mg on day 1 followed by 250mg per day for the next four days with amoxicillin/clavulanate 1 gr 3 times per day during 7 days. In case of allergy, amoxicillin/clavulanate can be replaced by a third-generation cephalosporin
Study NCT04363060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin/clavulanate
Description: Patients will receive amoxicillin/clavulanate 1 gr 3 times per day during 7 days. In case of allergy, amoxicillin/clavulanate can be replaced by a third-generation cephalosporin
Study NCT02484144 — intervention group
Intervention type: OTHER
Intervention: modern information
Description: information by video for coronarography
Study NCT02484144 — intervention group
Intervention type: OTHER
Intervention: usual information
Description: usual information for coronarography
Study NCT03983538 — intervention group
Intervention type: OTHER
Intervention: Mathematical modeling to predict response to chemotherapy
Description: Mathematical modeling using the patient's diagnostic core biopsy and baseline MRI of the breast will be used to predict the response to above therapy.
Study NCT02955953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2963016
Description: Administered SC
Study NCT01100853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VIVITROL injection and VIVITROL Placebo Injection , 24 weeks
Description: Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
Study NCT01100853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VIVITROL injection and VIVITROL Placebo Injection , 24 weeks
Description: Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
Study NCT02697643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BHCDS-based recommendations
Study NCT02697643 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-tailored recommendations
Study NCT03610893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone as perineural local anesthetic adjuvant
Study NCT03610893 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine as perineural local anesthetic adjuvant
Study NCT00169676 — intervention group
Intervention type: OTHER
Intervention: observation
Description: registry and database for surgery outcomes
Study NCT00629031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paromomycin
Description: 11 mg/kg for 14 days
Study NCT00629031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paromomycin
Description: Paromomycin for 21 days @ 11mg/kg by intramuscular injections
Study NCT00629031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paromomycin
Description: Paromomycin for 21 days @ 11mg/kg by intramuscular injections
Study NCT06550843 — intervention group
Intervention type: PROCEDURE
Intervention: mesentery-guided division
Description: In the Mes-G group, all surgeries were performed by one surgeon team (J.K.) from January 2013 using the following strategy for the proximal division site: the diseased bowel and para-intestinal mesentery were carefully compared by palpation and translucent observation through a shadowless lamp. The comparison was conducted from the diseased bowel towards the normal-appearing region upstream, to identify a point where the hypertrophied mesentery transitioned into normal thickness and softness and became translucent as observed through the shadowless lamp.
Study NCT03570216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test
Description: Participants will perform a graded cardiopulmonary exercise test to asses their cardiorespiratory fitness. It will also provide a peak exercise stimulus to examine acute changes in arterial stiffness, and to prescribe both moderate intensity continuous exercise and high intensity interval exercise.
Study NCT03570216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous exercise
Description: Participants will perform a 30-minute session of moderate-intensity continuous exercise.
Study NCT04074668 — intervention group
Intervention type: DRUG
Intervention: Iohexol Inj 300 milligrams/milliliter (mg/ml)
Description: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
Study NCT04074668 — intervention group
Intervention type: RADIATION
Intervention: PET/CT Scan
Description: Imaging used to visualize the kidneys and quantify renal metabolic activity
Study NCT04074668 — intervention group
Intervention type: PROCEDURE
Intervention: Renal Biopsy
Description: Minimally invasive outpatient procedure to obtain renal tissue after ultrasound visualization.
Study NCT03868787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS units are small, inexpensive, portable, battery-powered devices which deliver mild, alternating electrical currents via electrodes positioned on the skin near the anticipated dermatomal distribution of pain.
Study NCT03868787 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TENS
Description: Non-active TENS unit
Study NCT01598662 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirena (levonorgestrel-releasing intrauterine system)
Description: The Mirena IUD is a levonorgestrel-releasing IUD which contains 52 mg levonorgestrel total and releases 20 mcg of hormone daily.
Study NCT01598662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirena (levonorgestrel-releasing intrauterine system)
Description: The Mirena IUD is a levonorgestrel-releasing IUD which contains 52 mg levonorgestrel total and releases 20 mcg of hormone daily.
Study NCT04378673 — intervention group
Intervention type: OTHER
Intervention: not interventional
Description: This randomized controlled trial included data from 120 cases in the pediatric health and diseases department.
Study NCT06044038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Bi-weekly supervised physical activity intervention
Study NCT06044038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation program
Description: weekly 90-minute session consisting of welcoming participants, reviewing tasks conducted in the last meeting, and assignment of new pen-and-pencil cognitive and metacognitive tasks.
Study NCT06044038 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive rehabilitation program
Description: weekly 90-minute session consisting of welcoming participants, reviewing tasks conducted in the last meeting, and assignment of new pen-and-pencil cognitive and metacognitive tasks.
Study NCT02277184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ficlatuzumab
Description: Ficlatuzumab Concentrate for Injection, 20 mg/mL, is formulated in 10 mM histidine buffer pH 5.8. The formulation also includes 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product is sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials.The product is a clear to slightly opalescent, colorless to slightly yellow, solution.~Ficlatuzumab Concentrate for Injection is to be administered by IV infusion as an admixture with normal saline solution. The admixture solution in an IV bag is connected to an infusion set containing a 0.22 µm low protein-binding in line filter. The filtered admixture solution is clear to slightly opalescent.~Ficlatuzumab is to be stored under refrigerated conditions (2C - 8C)
Study NCT03570216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise
Description: 1 week later, participants will perform a 19-minute session of high-intensity interval exercise.
Study NCT02958787 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation Therapy Using MRI Based Treatment Planning